My colleague, Richard Rauck, M.D., Pain Fellowship Director at the Wake Forest University of Medicine, and I presented a Continuing Medical Education (CME) symposium at the meeting on atypical opioid options. We discussed the strengths and weakness of three atypical opioids—tramadol, tapentadol, and buprenorphine—that clinicians may consider for the appropriate patients.